Beta-blockers in dilated cardiomyopathies: they work.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Congestive cardiomyopathy (COCM) with severe dilatation and heart failure has a poor prognosis.
• High circulating catecholamines and resting tachycardia are common in COCM, potentially linked to pathogenesis.
• Spontaneous recovery rates in COCM are low.

Purpose of the Study:

• To evaluate the efficacy of chronic beta-blockade in patients with congestive cardiomyopathy.
• To assess the impact of beta-blockers on cardiac function, heart size, and survival in COCM.
• To investigate the role of sympathetic stimulation in COCM pathogenesis.

Main Methods:

• A study involving COCM patients, initially those with tachycardia, later expanded to include patients without tachycardia.
• A placebo-controlled period preceded beta-blocker treatment in some patients to rule out spontaneous recovery.
• Long-term follow-up (6 and 24 months) assessed functional, echocardiographic, and hemodynamic parameters.

Main Results:

• Chronic beta-blockade improved cardiac function, evidenced by reduced heart size, increased ejection fraction, and improved working performance.
• Patients showed reduced third heart sound and rapid filling wave on apex cardiogram.
• Beta-blocker withdrawal led to functional decline and heart failure relapse in a significant proportion of patients.
• Beta-blocker treatment was associated with increased survival compared to matched controls.

Conclusions:

• Beta-blockade is effective in improving cardiac function and survival in congestive cardiomyopathy.
• Improved myocardial function and potentially altered sympathetic sensitivity contribute to the benefits of beta-blockers in COCM.
• Diastolic function changes may represent an early indicator of beta-blocker efficacy in COCM.